49 results
424B3
QLGN
Qualigen Therapeutics Inc
3 May 24
Prospectus supplement
1:50pm
certain fees and expenses incurred by us incident to the registration of the Resale Shares. Discounts, concessions, commissions and similar selling
POS AM
QLGN
Qualigen Therapeutics Inc
30 Apr 24
Prospectus update (post-effective amendment)
6:58pm
the registration or qualification requirement is available and is complied with.
We are required to pay certain fees and expenses incurred by us incident
8-K
EX-10.1
QLGN
Qualigen Therapeutics Inc
27 Feb 24
Entry into a Material Definitive Agreement
7:00am
and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance
424B3
QLGN
Qualigen Therapeutics Inc
29 Sep 23
Prospectus supplement
4:30pm
is available and is complied with.
We are required to pay certain fees and expenses incurred by us incident to the registration of the Resale Shares
POS AM
QLGN
Qualigen Therapeutics Inc
1 Sep 23
Prospectus update (post-effective amendment)
4:15pm
or qualification requirement is available and is complied with.
We are required to pay certain fees and expenses incurred by us incident
8-K
EX-2.1
yu9wnd2uyw0nol bd52
26 Jul 23
Entry into a Material Definitive Agreement
5:25pm
8-K
EX-10.3
ful8x 1tf
22 Dec 22
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-10.1
3on06k5lpdo1
22 Dec 22
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-10.2
c7jer98 quvz
1 Dec 21
Qualigen Therapeutics, Inc. Announces Closing of $8.82 Million Registered Direct Offering
3:39pm
8-K
EX-10.1
zw9r5kvh9
1 Dec 21
Qualigen Therapeutics, Inc. Announces Closing of $8.82 Million Registered Direct Offering
3:39pm
8-K
EX-3.1
zkpyqyi
13 Aug 21
Entry into a Material Definitive Agreement
4:05pm
8-K
EX-3.1
hcqnq vg3b20ziz22l
17 May 21
Amendments to Articles of Incorporation or Bylaws
5:21pm
10-KT
19t rwp6i7
31 Mar 21
Annual report (with FYE transition)
4:33pm
8-K
EX-10.1
wdaoeivrqlmbktsr
18 Dec 20
Qualigen Therapeutics, Inc. Announces Closing of $12 Million Registered Direct Offering
3:54pm
8-K
EX-10.2
vkqe40y5
18 Dec 20
Qualigen Therapeutics, Inc. Announces Closing of $12 Million Registered Direct Offering
3:54pm
8-K
EX-10.2
t0vkc6u
4 Aug 20
Qualigen Therapeutics, Inc. Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:25pm